Kunimasa, Kei
Nishino, Kazumi
Sato, Yoshiharu
Mori, Masahide
Ihara, Shoichi
Suzuki, Hidekazu
Nagatomo, Izumi
Kumagai, Toru
Morishima, Toshitaka
Imamura, Fumio
Article History
Received: 13 January 2022
Accepted: 2 August 2022
First Online: 8 August 2022
Competing interests
: This study supported by AstraZeneca fund. Dr. Kunimasa reports honoraria for lecture from AstraZeneca, Chugai Pharmaceutical and Novartis. Dr. Nishino reports a grant from Nippon Boehringer Ingelheim and honoraria for lecture from Chugai Pharmaceutical, AstraZeneca, Nippon Boehringer Ingelheim, Eli Lily Japan K.K, Roche Diagnostics, Novartis, Pfizer, Merk; Dr. Mori reports honoraria for lecture from AstraZeneca, MSD, Ono Pharmaceutical, Eli Lily Japan K.K, Boehringer Ingelheim, Novartis, Chugai Pharmaceutical, Taiho Pharmaceutical Co. Ltd, Kyowa-Kirin, Otsuka, Nihon-kayaku, Pfizer Japan Inc, Shionogi; Dr. Suzuki reports honoraria for lecture from AstraZeneca, Ono Pharmaceutical, Chugai Pharmaceutical, MSD, Bristol-Myers Squibb, Eli Lily Japan K.K; Dr. Nagatomo reports honoraria for lecture from AstraZeneca, Nippon Boehringer Ingelheim, Nippon Kayaku Co., Ltd, Eli Lily Japan K.K.; Dr. Kumagai reports grants from Ono Pharmaceutical, MSD, Chugai Pharceutical Co. Ltd, AstraZeneca, Takeda Pharmaceutical Companey Limited. Regeneron Pharmaceuticals, Inc. Merck Serono Co., Ltd. Pfizer Japan Inc. Taiho Pharmaceutical Co.,Ltd. Nippon Boehringer lngelheim Co., Ltd. Eli Lilly Japan. Novartis Pharma. AbbVie GK., Delta-Fly Pharma, Inc. The Osaka Foundation for The Prevention of Cancer and Life-style related Diseases (Public Interest Incorporated Foundation), and honoraria from Ono Pharmaceutical, AstraZeneca, Taiho Pharmaceutical Co. Ltd., MSD, TEIJIN PHARMA LIMITED, Novartis Pharma, Nippon Boehringer Ingelheim Co., Ltd. Eli Lily Japan. Pfizer Inc., Chugai Pharceutical Co. Ltd., Bristol-Myers Squibb; Dr. Imamura reports honoraria for lecture from AstraZeneca, Chugai Pharma and Nippon Boehringer Ingelheim, and other authors have no conflict of interest.